[1] Chen ZC, Li GL, Liu J.  Autonomic dysfunction in Parkinson's disease: implications for pathophysiology, diagnosis, and treatment[J]. Neurobiol Dis, 2020, 134: 104700-.   doi: 10.1016/j.nbd.2019.104700
[2]

Lamotte G, Holmes C, Sullivan P, et al. Cardioselective peripheral noradrenergic deficiency in Lewy body synucleinopathies[J/OL]. Ann Clin Transl Neurol, 2020, 7(12): 2450−2460[2021-02-21]. https://onlinelibrary.wiley.com/doi/10.1002/acn3.51243. DOI: 10.1002/acn3.51243.
[3] Becker G, Bahri AM, Michel A, et al.  Comparative assessment of 6-[18F]fluoro-L-m-tyrosine and 6-[18F]fluoro-L-dopa to evaluate dopaminergic presynaptic integrity in a Parkinson's disease rat model[J]. J Neurochem, 2017, 141(4): 626-635.   doi: 10.1111/jnc.14016
[4] Malpartida AB, Williamson M, Narendra DP, et al.  Mitochondrial dysfunction and mitophagy in parkinson's disease: from mechanism to therapy[J]. Trends Biochem Sci, 2021, 46(4): 329-343.   doi: 10.1016/j.tibs.2020.11.007
[5] Postuma RB, Berg D, Stern M, et al.  MDS clinical diagnostic criteria for Parkinson's disease[J]. Mov Disord, 2015, 30(12): 1591-1601.   doi: 10.1002/mds.26424
[6] Takahashi M, Ikemura M, Oka T, et al.  Quantitative correlation between cardiac MIBG uptake and remaining axons in the cardiac sympathetic nerve in Lewy body disease[J]. J Neurol Neurosurg Psychiatry, 2015, 86(9): 939-944.   doi: 10.1136/jnnp-2015-310686
[7] Kuten J, Linevitz A, Lerman H, et al.  [18F] FDOPA PET may confirm the clinical diagnosis of Parkinson's disease by imaging the nigro-striatal pathway and the sympathetic cardiac innervation: proof-of-concept study[J]. J Integr Neurosci, 2020, 19(3): 489-494.   doi: 10.31083/j.jin.2020.03.196
[8]

Metzger JM, Lopez SM, Schmidt JK, et al. Effects of cardiac sympathetic neurodegeneration and PPARγ activation on rhesus macaque whole blood miRNA and mRNA expression profiles[J/OL]. Biomed Res Int, 2020, 2020: 9426204[2021-02-21]. https://www.hindawi.com/journals/bmri/2020/9426204. DOI: 10.1155/2020/9426204.
[9]

Skowronek C, Zange L, Lipp A. Cardiac 123I-MIBG scintigraphy in neurodegenerative Parkinson syndromes: performance and pitfalls in clinical practice[J/OL]. Front Neurol, 2019, 10: 152[2021-02-21]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399127. DOI: 10.3389/fneur.2019.00152.
[10] Uyama N, Otsuka H, Shinya T, et al.  The utility of the combination of a SPECT study with [123I]-FP-CIT of dopamine transporters and [123I]-MIBG myocardial scintigraphy in differentiating Parkinson disease from other degenerative parkinsonian syndromes[J]. Nucl Med Commun, 2017, 38(6): 487-492.   doi: 10.1097/mnm.0000000000000674
[11] Yoshii F, Ryo M, Baba Y, et al.  Combined use of dopamine transporter imaging (DAT-SPECT) and 123I-metaiodobenzylguanidine (MIBG) myocardial scintigraphy for diagnosing Parkinson's disease[J]. J Neurol Sci, 2017, 375: 80-85.   doi: 10.1016/j.jns.2017.01.042
[12] Goldstein DS, Cheshire Jr WP.  Roles of cardiac sympathetic neuroimaging in autonomic medicine[J]. Clin Auton Res, 2018, 28(4): 397-410.   doi: 10.1007/s10286-018-0547-6
[13] 王煜, 阚英, 王巍, 等.  123I-MIBG和131I-MIBG心肌显像在帕金森病患者中的对比研究[J]. 临床和实验医学杂志, 2020, 19(18): 1926-1930.   doi: 10.3969/j.issn.1671-4695.2020.18.007
Wang Y, Kan Y, Wang W, et al.  Comparative study of 123I-MIBG and 131I-MIBG myocardial imaging in patients with Parkinson's disease[J]. J Clin Exp Med, 2020, 19(18): 1926-1930.   doi: 10.3969/j.issn.1671-4695.2020.18.007
[14]

Stormezand GN, Chaves LT, García DV, et al. Intrastriatal gradient analyses of 18F FDOPA PET scans for differentiation of Parkinsonian disorders[J/OL]. Neuroimage Clin, 2020, 25: 102161[2021-02-21]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6976972. DOI: 10.1016/j.nicl.2019.102161.
[15]

Pain CD, O'Keefe GJ, Ackermann U, et al. Human biodistribution and internal dosimetry of 4-[18F]fluorobenzyl-dexetimide: a PET radiopharmaceutical for imaging muscarinic acetylcholine receptors in the brain and heart[J/OL]. EJNMMI Res, 2020, 10(1): 61[2021-02-21]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292855. DOI: 10.1186/s13550-020-00641-1.
[16] Hiroshima Y, Manabe O, Naya M, et al.  Quantification of myocardial blood flow with 11C-hydroxyephedrine dynamic PET: comparison with 15O-H2O PET[J]. J Nucl Cardiol, 2020, 27(4): 1118-1125.   doi: 10.1007/s12350-017-1140-4
[17] Wang JZ, Moody JB, Kaps N, et al.  Reproducible quantification of regional sympathetic denervation with [11C]meta-hydroxyephedrine PET imaging[J]. J Nucl Cardiol, 2021, 28(6): 2745-2757.   doi: 10.1007/s12350-020-02114-3
[18] Boutagy NE, Sinusas AJ.  Recent advances and clinical applications of PET cardiac autonomic nervous system imaging[J]. Curr Cardiol Rep, 2017, 19(4): 33-.   doi: 10.1007/s11886-017-0843-0
[19] Matsusue E, Fujihara Y, Tanaka K, et al.  The utility of the combined use of 123I-FP-CIT and 123I-MIBG myocardial scintigraphy in differentiating Parkinson's disease from other parkinsonian syndromes[J]. Yonago Acta Med, 2018, 61(2): 117-127.   doi: 10.33160/yam.2018.06.004
[20] Nuvoli S, Spanu A, Fravolini ML, et al.  [123I]metaiodobenzylguanidine (MIBG) cardiac scintigraphy and automated classification techniques in Parkinsonian disorders[J]. Mol Imaging Biol, 2020, 22(3): 703-710.   doi: 10.1007/s11307-019-01406-6
[21] Yang TF, Wang L, Li Y, et al.  131I-MIBG myocardial scintigraphy for differentiation of Parkinson's disease from multiple system atrophy or essential tremor in Chinese population[J]. J Neurol Sci, 2017, 373: 48-51.   doi: 10.1016/j.jns.2016.12.006
[22] Lamotte G, Holmes C, Wu TX, et al.  Long-term trends in myocardial sympathetic innervation and function in synucleinopathies[J]. Parkinsonism Relat Disord, 2019, 67: 27-33.
[23] Marino BLB, de Souza LR, Sousa KPA, et al.  Parkinson's disease: a review from pathophysiology to treatment[J]. Mini Rev Med Chem, 2020, 20(9): 754-767.   doi: 10.2174/1389557519666191104110908
[24]

Chagraoui A, Boulain M, Juvin L, et al. L-DOPA in Parkinson's disease: looking at the "false" neurotransmitters and their meaning[J/OL]. Int J Mol Sci, 2020, 21(1): 294[2021-02-21]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6981630. DOI: 10.3390/ijms21010294.
[25] Armstrong MJ, Okun MS.  Diagnosis and treatment of Parkinson disease: a review[J]. JAMA, 2020, 323(6): 548-560.   doi: 10.1001/jama.2019.22360
[26] Zhu Y, Matsumura Y, Velayutham M, et al.  Reactive oxygen species scavenging with a biodegradable, thermally responsive hydrogel compatible with soft tissue injection[J]. Biomaterials, 2018, 177: 98-112.   doi: 10.1016/j.biomaterials.2018.05.044
[27] Mukherjee UA, Ong SB, Ong SG, et al.  Parkinson's disease proteins: novel mitochondrial targets for cardioprotection[J]. Pharmacol Ther, 2015, 156: 34-43.   doi: 10.1016/j.pharmthera.2015.10.005
[28] Goldstein DS.  The catecholaldehyde hypothesis: where MAO fits in[J]. J Neural Transm, 2020, 127(2): 169-177.   doi: 10.1007/s00702-019-02106-9